Axa S.A. Has $1.14 Million Holdings in Zai Lab Limited (NASDAQ:ZLAB)

Axa S.A. trimmed its stake in shares of Zai Lab Limited (NASDAQ:ZLAB) by 12.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 65,814 shares of the company’s stock after selling 9,126 shares during the period. Axa S.A. owned approximately 0.07% of Zai Lab worth $1,141,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. TD Asset Management Inc lifted its holdings in Zai Lab by 8.6% during the 4th quarter. TD Asset Management Inc now owns 235,570 shares of the company’s stock worth $6,438,000 after buying an additional 18,600 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Zai Lab during the fourth quarter valued at $432,000. Brilliance Asset Management Ltd. boosted its holdings in Zai Lab by 177.5% in the fourth quarter. Brilliance Asset Management Ltd. now owns 435,926 shares of the company’s stock valued at $11,914,000 after acquiring an additional 278,841 shares during the last quarter. Sectoral Asset Management Inc. increased its position in Zai Lab by 33.3% in the fourth quarter. Sectoral Asset Management Inc. now owns 4,000 shares of the company’s stock worth $109,000 after purchasing an additional 1,000 shares during the period. Finally, Bellevue Group AG acquired a new stake in Zai Lab in the fourth quarter worth about $3,714,000. 41.65% of the stock is owned by institutional investors.

Zai Lab Trading Up 3.0 %

Shares of ZLAB opened at $24.86 on Wednesday. The stock has a market cap of $2.48 billion, a P/E ratio of -6.95 and a beta of 1.07. Zai Lab Limited has a 1 year low of $13.48 and a 1 year high of $31.22. The stock’s 50-day moving average price is $19.23 and its two-hundred day moving average price is $18.15.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.16). Zai Lab had a negative return on equity of 37.96% and a negative net margin of 92.44%. The firm had revenue of $100.50 million for the quarter, compared to the consensus estimate of $94.46 million. As a group, equities analysts forecast that Zai Lab Limited will post -2.95 EPS for the current year.

Insider Transactions at Zai Lab

In related news, insider Joshua L. Smiley sold 4,352 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $16.67, for a total value of $72,547.84. Following the completion of the sale, the insider now owns 43,232 shares in the company, valued at approximately $720,677.44. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ZLAB. JPMorgan Chase & Co. reduced their target price on shares of Zai Lab from $43.00 to $38.00 and set an “overweight” rating on the stock in a research note on Friday, July 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a report on Wednesday, August 7th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $58.97.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.